G6PD Operational Research Community of Practice
Advancing the use of G6PD tests at the point of care
The G6PD Operations Research Community of Practice (GORCoP) is a collaboration of researchers, organizations, malaria control programs, and clinicians committed to advancing the introduction and scale-up of glucose-6-phosphate dehydrogenase (G6PD) diagnostics in support of safe access to radical cure treatment for Plasmodium vivax malaria through operations research. There are several G6PD diagnostics available now and in the pipeline that have the potential to expand access to safe radical cure. The GORCoP seeks to understand and prepare for the transitions that health systems will need to undergo to adopt these tests.
This community of practice aims to harness best practices and lessons learned from multiple stakeholders, benefiting from the expertise of participants in areas such as diagnostic introduction, operations research, implementation science, quality assurance, and training. To support information sharing, the GORCoP maintains a digital central repository of resources that is accessible to all participants, hosts meetings and presentations, provides ongoing updates, and creates connections among participants.
The GORCoP maintains a digital repository of resources to support collaboration between national malaria control programs, researchers, and institutions working to advance the use of G6PD tests at the point of care. These resources include:
- Training materials.
- Quality assurance materials.
- Patient education materials.
- Sample protocols.
- Lessons learned from introducing G6PD tests
- Frequently asked questions about the STANDARD G6PD Test
Several public resources can be downloaded below. Join the community of practice for access to all resources.
Members of the community of practice are invited to join live webinars for presentations and discussions on the latest developments within G6PD operational research. These topics include lessons learned during training, research or implementations, and ethics and quality assurance for point-of-care testing.
Date: September 30th, 7:00 pm PDT / October 1st, 9:00 am ICT
Angela Devine from the Menzies School of Health Research and University of Melbourne will conduct an interactive session on an new interactive tool for assessing the cost-effectiveness of radical cure options.
Quantitative and qualitative screening for glucose-6-phosphate dehydrogenase (G6PD) deficiency and tafenoquine provide new opportunities for the treatment and control of Plasmodium vivax malaria. We have built an interactive online tool to help malaria control programs and decision makers start to think about the cost-effectiveness of different options for the radical cure of vivax malaria. It compares the following strategies: (1) unsupervised primaquine without G6PD screening, (2) unsupervised primaquine after screening with a qualitative G6PD test, (3) unsupervised primaquine after screening with a quantitative G6PD test, and (4) tafenoquine after screening with a quantitative G6PD test. This presentation will provide an overview of the tool and demonstrate its features while giving instructions to the attendees on how to use the tool on their own. As the tool is under development, this will be an interactive session and attendees will be encouraged to provide feedback on what would improve its usefulness.
September 14, 2021 webinar: The validation and operational use of point-of-care G6PD testing in the Brazilian Amazon: a presentation of data from clinical study and real-life settings to inform test performance and considerations for use.
Stephanie Zobrist and Jose Diego Brito-Sousa presented data generated in two distinct research settings: a highly controlled clinical validation trial and municipal vivax malaria diagnostic units in the Amazonas and Rondônia states of Brazil. Their presentations will highlight key aspects of the performance and operational use in both settings, relevant distinctions, and discuss the implications of those differences for program planning and patient care.
THREE PART webinar series on interpreting quantitative G6PD test results at the point of care.
In part two of this series, Dr. Benedikt Ley from the Menzies School of Health Research presents the outcomes of the multi-laboratory assessment conducted by FIND and Menzies on the repeatability and reproducibility of the STANDARD G6PD Test.
In part two of this series, Pooja Bansil and Emily Gerth-Guyette from PATH discuss the interpretation of a point-of-care G6PD test, the STANDARD™ G6PD Test, and provide practical guidance on interpreting a quantitative result and using it for a semi-quantitative classification of G6PD status.
In part one of this series, Daniel Pfeffer, from the Menzies School of Health Research and Dr. Gonzalo Domingo, Scientific Director and malaria diagnostics lead at PATH explore the underlying epidemiology and case definitions used to evaluate point-of-care tests for G6PD deficiency and the implications on diagnostic performance.
January 19, 2021 webinar: Early experiences with point-of-care G6PD testing in malaria case management.
Scientists from UCSF, CMPE, PATH, and CHAI shared their early experiences and challenges of incorporating point-of-care testing for G6PD deficiency with Plasmodium vivax malaria case management in Laos, Cambodia, and Vietnam.
July 14, 2020 webinar: User perspectives on a quantitative G6PD test in Bangladesh. In this part two of the series on user perspectives from G6PD testing activities in Bangladesh, Nora Engel and Cristian Traian Ghergu from Maastricht University present a qualitative study that evaluated user perspectives on a quantitative G6PD test to support radical cure of P. vivax malaria in Bangladesh.
July 7, 2020 webinar: A training for health service providers on the SD Biosensor STANDARD G6PD test in Bangladesh. Mohammad Shafiul Alam, Associate Scientist at the Emerging Infections & Parasitology Laboratory of icddr,b, discussed the operations and findings from a training workshop for health service providers to support the implementation of the SD Biosensor STANDARD G6PD test in health facilities in Bangladesh.
April 7, 2020 webinar: Training healthcare providers for point of care G6PD testing in Brazil. Jose Diego de Brito Sousa, MSc, a Clinical Lab Scientist at the Amazonas State University in Brazil, discussed his experiences training healthcare providers to use the STANDARD G6PD test for the ongoing SAFEPRIM study in Manaus and Porto Velho. Diego also shared his experience working with both CareStart and STANDARD G6PD tests and his reasoning for preferring one test over the other.
October 30, 2019 webinar: Communicating Results and Counseling. Nicole van der Merwe, Ph.D., discussed foundational principles that genetic counselors use to ethically communicate individual findings. Eva Maria Cutiongco-De La Paz, MD, shared themes from the approach to counseling for G6PD as part of the Philippines National Institute of Health’s newborn screening program.
July 16, 2019 webinar: An Introduction to Quality Assurance in G6PD Testing. Germana Bancone, a research scientist with Shoklo Malaria Research Unit (SMRU), presented an introduction to quality assurance in G6PD testing. Maria Kahn, a senior research associate at PATH, discussed the importance of using control reagents in qualitative point-of-care assays for G6PD testing
April 10, 2019 webinar: G6PD Usability Testing and User Considerations. PATH shared results of usability testing from current quantitative G6PD tests and training materials that can be adapted for other operations research studies. Fundação de Medicina Tropical Doutor Heitor Vieira Dourado (FMT-HVD) presented training methods and materials from the SAFEPRIM study and Armed Forces Research Institute of Medical Sciences (AFRIMS) shared their diagnostic introduction activities in Cambodia.
For more information, please reach out to GORCoP@path.org.
This G6PD Operational Research Community of Practice is funded by grants from the Foreign, Commonwealth & Development Office (FDCO) and the Bill & Melinda Gates Foundation.